Enovis (ENOV)
Builds orthopedic implants, bracing, rehabilitation, and recovery products for care teams and patients.
$18.37
vs last close+0.33 (+1.83%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Apr 2025 | Q2 FY25Jul 2025 | Q3 FY25Oct 2025 | Q4 FY25Dec 2025 | Q1 FY26Apr 2026 | Q2 FY26Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 418 | 455 | 516 | 525 | 505 | 561 | 559 | 565 | 549 | 576 | 589 | 583 |
| Cost of revenue | 175 | 191 | 218 | 236 | 219 | 253 | 227 | 230 | 262 | 226 | 266 | 224 |
| Gross profit | 243 | 264 | 298 | 289 | 286 | 308 | 332 | 335 | 287 | 349 | 324 | 359 |
| 263 | 270 | 333 | 333 | 318 | 972 | 375 | 351 | 278 | 301 | 303 | 342 | |
| Research & development | 20 | 18 | 23 | 23 | 20 | 24 | 29 | 31 | 30 | 31 | 32 | 32 |
| 204 | 211 | 256 | 264 | 250 | 258 | 269 | 267 | 248 | 270 | 272 | 264 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 264 |
| Other expenses | 39 | 41 | 54 | 46 | 48 | 691 | 78 | 53 | 0 | −1 | 0 | 46 |
| Operating income | −20 | −6 | −35 | −44 | −32 | −665 | −43 | −16 | 9 | 48 | 20 | 17 |
| −5 | 13 | −44 | 17 | −11 | −9 | −14 | −10 | −576 | −558 | −20 | −10 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 10 | 0 |
| Interest expense | 6 | 4 | 20 | 17 | 11 | 9 | 9 | 9 | 21 | 8 | 19 | 8 |
| Other non-operating income | −1 | −18 | 24 | −34 | 0 | 0 | 5 | 0 | 555 | 550 | 0 | 2 |
| Income before tax | −26 | 8 | −79 | −27 | −43 | −674 | −57 | −26 | −567 | −510 | 1 | 7 |
| Income tax expense | −6 | 5 | −7 | −9 | −9 | 30 | −2 | 11 | 4 | 9 | 9 | 9 |
| Net income from continuing operations | −19 | 3 | −72 | −18 | −34 | −704 | −56 | −36 | −571 | −519 | −8 | −1 |
| Discontinued operations | 17 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | −2 | 0 | 0 |
| Net income | −3 | 3 | −72 | −19 | −32 | −703 | −56 | −37 | −571 | −521 | −9 | −1 |
| EPS, basic | −$0.34 | $0.05 | −$1.32 | −$0.34 | −$0.57 | −$12.05 | −$0.99 | −$0.64 | −$10.06 | −$9.17 | −$0.15 | −$0.02 |
| EPS, diluted | −$0.34 | $0.05 | −$1.32 | −$0.34 | −$0.57 | −$12.05 | −$0.99 | −$0.64 | −$10.06 | −$9.17 | −$0.15 | −$0.02 |
| Weighted average shares, basic | 55 | 55 | 55 | 55 | 56 | 58 | 57 | 57 | 57 | 57 | 57 | 58 |
| Weighted average shares, diluted | 55 | 55 | 55 | 55 | 56 | 58 | 57 | 57 | 57 | 57 | 57 | 58 |
| EBITDA | 36 | 69 | 14 | 55 | 40 | −590 | 23 | 55 | −472 | −425 | 93 | 87 |
| Depreciation & amortization | 55 | 57 | 73 | 66 | 71 | 74 | 71 | 72 | 74 | 77 | 73 | 71 |
| EBIT | −20 | 12 | −59 | −10 | −32 | −665 | −48 | −16 | −546 | −502 | 20 | 16 |
